Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Zogenix Inc (ZGNX)

Zogenix Inc (ZGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zogenix Inc 5959 Horton Street Suite 500 EMERYVILLE CA 94608 USA

www.zogenix.com P: 510-550-8300

Description:

Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome.

Key Statistics

Overview:

Market Capitalization, $K 1,500,136
Shares Outstanding, K 56,227
Annual Sales, $ 81,690 K
Annual Net Income, $ -227,410 K
Last Quarter Sales, $ 22,610 K
Last Quarter Net Income, $ -58,000 K
60-Month Beta 0.89
% of Insider Shareholders 4.10%
Float, K 53,922
% Float 95.90%

Growth:

1-Year Return 31.69%
3-Year Return -47.63%
5-Year Return 147.04%
5-Year Revenue Growth -49.82%
5-Year Earnings Growth -89.27%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.98 on 02/28/22
Latest Earnings Date 02/24/22
Earnings Per Share ttm -4.27
EPS Growth vs. Prev Qtr 5.77%
EPS Growth vs. Prev Year 16.95%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 07/01/15

ZGNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -91.20%
Return-on-Assets % -43.60%
Profit Margin % -278.38%
Debt/Equity 0.88
Price/Sales 18.07
Price/Cash Flow N/A
Price/Book 8.35
Book Value/Share 4.01
Interest Coverage -59.32
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar